CELC
Celcuity Inc. NASDAQ Listed Sep 20, 2017$130.93
After hrs
$131.06
+0.00%
Mkt Cap $6.3B
52w Low $9.51
85.8% of range
52w High $151.02
50d MA $117.00
200d MA $86.76
P/E (TTM)
-33.2x
EV/EBITDA
-30.6x
P/B
65.7x
Debt/Equity
1.9x
ROE
-176.1%
P/FCF
-34.1x
RSI (14)
—
ATR (14)
—
Beta
0.42
50d MA
$117.00
200d MA
$86.76
Avg Volume
739.7K
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
16305–36th Avenue North · Minneapolis, MN 55446 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | AMC | -1.06 | -0.97 | +8.5% | 110.22 | -0.9% | +4.2% | -3.8% | -1.8% | +3.6% | +2.5% | — |
| Nov 12, 2025 | AMC | -1.02 | -0.92 | +9.8% | 85.15 | +0.0% | +1.0% | +8.8% | +8.3% | +7.6% | +10.7% | — |
| Aug 14, 2025 | AMC | -0.90 | -1.04 | -15.6% | 51.89 | +2.0% | -0.2% | -0.6% | -5.1% | -6.0% | -2.9% | — |
| May 14, 2025 | AMC | -0.95 | -0.86 | +9.5% | 10.86 | +0.0% | -3.1% | -2.3% | -1.6% | -1.9% | -2.4% | — |
| Mar 31, 2025 | AMC | -0.72 | -0.85 | -18.1% | 10.11 | -1.5% | -8.1% | -7.4% | -12.5% | -14.4% | -9.4% | — |
| Nov 14, 2024 | AMC | -0.65 | -0.70 | -7.7% | 14.11 | -0.3% | -10.3% | -11.7% | -11.6% | -9.4% | -9.8% | — |
| Aug 14, 2024 | AMC | -0.71 | -0.62 | +12.7% | 16.33 | +5.8% | -3.4% | +1.3% | +6.1% | +4.3% | +4.0% | — |
| May 15, 2024 | AMC | -0.71 | -0.64 | +9.9% | 17.23 | +13.0% | +2.5% | -2.7% | -2.5% | -4.2% | -7.2% | — |
| Mar 27, 2024 | AMC | -0.71 | -0.65 | +8.5% | 18.16 | -0.9% | +18.9% | +14.4% | +8.1% | +10.1% | +9.6% | — |
| Nov 13, 2023 | AMC | -0.74 | -0.83 | -12.2% | 10.89 | +4.3% | +10.1% | +11.6% | +12.3% | +17.4% | +20.1% | — |
| Aug 10, 2023 | AMC | -0.67 | -0.66 | +1.5% | 10.00 | -2.2% | -1.1% | -2.1% | -1.3% | -5.0% | -4.6% | — |
| May 15, 2023 | AMC | -0.65 | -0.55 | +15.4% | 9.58 | -6.1% | +3.0% | +4.6% | +3.5% | +5.4% | +10.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4 | H.C. Wainwright | Upgrade | Neutral → Buy | $165 | $125.65 | $142.12 | +13.1% | +15.4% | +12.8% | +11.0% | +4.0% | — |
| Apr 27 | Citizens | Initiates | Mkt Outperform | $150 | $121.03 | $121.70 | +0.6% | +3.8% | -0.8% | -1.7% | +0.3% | +3.8% |
| Mar 26 | Stifel | Maintains | Buy → Buy | — | $110.22 | $109.25 | -0.9% | +4.2% | -3.8% | -1.8% | +3.6% | +2.5% |
| Mar 26 | Needham | Maintains | Buy → Buy | — | $110.22 | $109.25 | -0.9% | +4.2% | -3.8% | -1.8% | +3.6% | +2.5% |
| Mar 17 | Needham | Maintains | Buy → Buy | — | $114.90 | $115.00 | +0.1% | -0.7% | -2.1% | -1.7% | -7.7% | -7.1% |
| Mar 10 | Needham | Maintains | Buy → Buy | — | $113.45 | $115.48 | +1.8% | +3.2% | +2.0% | -2.4% | +0.7% | +1.3% |
| Dec 2 | Jefferies | Maintains | Buy → Buy | — | $98.49 | $100.00 | +1.5% | -1.0% | +1.5% | +7.5% | +7.2% | +5.6% |
| Nov 17 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $92.68 | $90.40 | -2.5% | -0.5% | -1.2% | +1.7% | +1.4% | +5.2% |
| Nov 13 | Craig-Hallum | Maintains | Buy → Buy | — | $85.15 | $85.15 | +0.0% | +1.0% | +8.8% | +8.3% | +7.6% | +10.7% |
| Nov 13 | Stifel | Maintains | Buy → Buy | — | $85.15 | $85.15 | +0.0% | +1.0% | +8.8% | +8.3% | +7.6% | +10.7% |
| Oct 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $65.50 | $65.00 | -0.8% | +6.9% | +7.7% | +8.4% | +18.3% | +13.6% |
| Oct 20 | Needham | Maintains | Buy → Buy | — | $51.96 | $79.23 | +52.5% | +35.8% | +26.1% | +34.8% | +35.8% | +36.6% |
| Oct 3 | Needham | Maintains | Buy → Buy | — | $49.42 | $49.40 | -0.0% | +2.2% | -3.3% | -0.4% | +0.2% | +0.1% |
| Aug 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $51.79 | $52.69 | +1.7% | -0.4% | -5.0% | -5.8% | -2.7% | +1.2% |
| Aug 15 | Needham | Maintains | Buy → Buy | — | $51.89 | $52.92 | +2.0% | -0.2% | -0.6% | -5.1% | -6.0% | -2.9% |
| Jul 28 | Needham | Maintains | Buy → Buy | — | $13.77 | $45.96 | +233.8% | +167.2% | +179.6% | +192.7% | +184.5% | +189.8% |
| Jul 28 | Leerink Partners | Maintains | Outperform → Outperform | — | $13.77 | $45.96 | +233.8% | +167.2% | +179.6% | +192.7% | +184.5% | +189.8% |
| Jul 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.77 | $45.96 | +233.8% | +167.2% | +179.6% | +192.7% | +184.5% | +189.8% |
| Jun 30 | Needham | Maintains | Buy → Buy | — | $12.54 | $12.92 | +3.0% | +6.5% | -0.4% | +4.0% | +10.0% | +6.4% |
| May 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.61 | $10.60 | -0.1% | +0.8% | +0.4% | -0.1% | +1.3% | -1.6% |
| May 15 | Needham | Maintains | Buy → Buy | — | $10.86 | $10.86 | +0.0% | -3.1% | -2.3% | -1.6% | -1.9% | -2.4% |
| Apr 11 | Needham | Maintains | Buy → Buy | — | $8.65 | $8.64 | -0.1% | +6.7% | +12.7% | +16.9% | +15.5% | +18.4% |
| Apr 1 | Needham | Maintains | Buy → Buy | — | $10.11 | $9.96 | -1.5% | -8.1% | -7.4% | -12.5% | -14.4% | -9.4% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.11 | $9.96 | -1.5% | -8.1% | -7.4% | -12.5% | -14.4% | -9.4% |
| Feb 6 | Needham | Maintains | Buy → Buy | — | $12.74 | $12.85 | +0.9% | -1.2% | -3.8% | -6.8% | -5.0% | -2.6% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.11 | $14.07 | -0.3% | -10.3% | -11.7% | -11.6% | -9.4% | -9.8% |
| Nov 15 | Needham | Maintains | Buy → Buy | — | $14.11 | $14.07 | -0.3% | -10.3% | -11.7% | -11.6% | -9.4% | -9.8% |
| Oct 7 | Stifel | Maintains | Buy → Buy | — | $15.04 | $15.22 | +1.2% | +1.5% | +1.5% | -4.5% | -3.6% | +0.8% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.33 | $17.27 | +5.8% | -3.4% | +1.3% | +6.1% | +4.3% | +4.0% |
| Aug 15 | Stifel | Maintains | Buy → Buy | — | $16.33 | $17.27 | +5.8% | -3.4% | +1.3% | +6.1% | +4.3% | +4.0% |
| Aug 15 | Needham | Maintains | Buy → Buy | — | $16.33 | $17.27 | +5.8% | -3.4% | +1.3% | +6.1% | +4.3% | +4.0% |
| May 31 | Needham | Maintains | Buy → Buy | — | $15.10 | $15.11 | +0.1% | +4.6% | -0.9% | -1.8% | -6.6% | -5.0% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.23 | $19.47 | +13.0% | +2.5% | -2.7% | -2.5% | -4.2% | -7.2% |
| May 16 | Stifel | Maintains | Buy → Buy | — | $17.23 | $19.47 | +13.0% | +2.5% | -2.7% | -2.5% | -4.2% | -7.2% |
| May 16 | Needham | Maintains | Buy → Buy | — | $17.23 | $19.47 | +13.0% | +2.5% | -2.7% | -2.5% | -4.2% | -7.2% |
| Apr 12 | Needham | Maintains | Buy → Buy | — | $19.69 | $19.60 | -0.5% | -7.0% | -8.1% | -12.5% | -13.6% | -16.8% |
| Mar 28 | Needham | Maintains | Buy → Buy | — | $18.16 | $18.00 | -0.9% | +18.9% | +14.4% | +8.1% | +10.1% | +9.6% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.16 | $18.00 | -0.9% | +18.9% | +14.4% | +8.1% | +10.1% | +9.6% |
| Mar 28 | Craig-Hallum | Maintains | Buy → Buy | — | $18.16 | $18.00 | -0.9% | +18.9% | +14.4% | +8.1% | +10.1% | +9.6% |
| Nov 13 | Needham | Maintains | Buy → Buy | — | $10.77 | $10.89 | +1.1% | +1.1% | +11.3% | +12.8% | +13.6% | +18.7% |
| Sep 22 | Needham | Maintains | Buy → Buy | — | $9.94 | $9.97 | +0.3% | +0.3% | -3.7% | -3.2% | -3.9% | -5.4% |
| Aug 11 | Needham | Maintains | Buy → Buy | — | $10.00 | $9.78 | -2.2% | -1.1% | -2.1% | -1.3% | -5.0% | -4.6% |
| May 16 | Needham | Maintains | Buy → Buy | — | $9.58 | $9.00 | -6.1% | +3.0% | +4.6% | +3.5% | +5.4% | +10.6% |
| Mar 27 | Needham | Maintains | Buy → Buy | — | $9.51 | $9.55 | +0.4% | +13.6% | +9.1% | +8.4% | +8.9% | +7.8% |
| May 17 | Needham | Maintains | Buy → Buy | — | $5.66 | $5.83 | +3.0% | -2.8% | -2.7% | -0.7% | +0.7% | +18.4% |
| Oct 8 | Canaccord Genuity | Maintains | Buy → Buy | — | $16.95 | $17.84 | +5.3% | +1.0% | +3.8% | +3.7% | +11.3% | +9.8% |
| Sep 7 | Jefferies | Maintains | Buy → Buy | — | $21.50 | $22.83 | +6.2% | +1.3% | +1.9% | +1.3% | -1.5% | -0.2% |
| Jul 29 | Cowen & Co. | Maintains | Outperform → Outperform | — | $20.50 | $20.99 | +2.4% | +3.9% | -3.9% | -1.4% | -0.7% | -2.4% |
| Jul 27 | Needham | Maintains | Buy → Buy | — | $20.68 | $21.00 | +1.5% | -1.8% | -0.9% | +2.9% | -4.7% | -2.3% |
| Feb 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.46 | $16.13 | -2.0% | +1.8% | +1.0% | +8.1% | +0.9% | -4.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | Buller Richard E | — | Sell | 365 | $143.24 | $52K | 6,760 | -6.26% | — |
| May 4, 2026 | Buller Richard E | — | Sell | 2,825 | $142.04 | $401K | 7,125 | -6.26% | — |
| May 4, 2026 | Buller Richard E | — | Sell | 2,301 | $141.03 | $325K | 9,950 | -6.26% | — |
| May 4, 2026 | Buller Richard E | — | Sell | 1,670 | $139.58 | $233K | 12,251 | -6.26% | — |
| May 4, 2026 | Buller Richard E | — | Sell | 550 | $139.00 | $76K | 13,921 | -6.26% | — |
| May 4, 2026 | Buller Richard E | — | Sell | 1,289 | $137.00 | $177K | 14,471 | -6.26% | — |
| May 4, 2026 | Dalvey David | — | Sell | 25,000 | $140.68 | $3.5M | 65,000 | -6.26% | — |
8-K
Unknown — 8-K Filing
CELC's 2025 full-year results and corporate update will reveal cash runway, development progress on oncology therapies, and whether the biotech has sufficient funding for upcoming clinical milestones—critical metrics determining survival probability and stock viability.
Mar 25
8-K · 5.02
!!! Very High
Celcuity Inc. -- 8-K 5.02: Executive Change
Celcuity appointed Mr. Romp to its board of directors, strengthening governance and potentially signaling management's confidence in strategic direction.
Feb 12
Data updated apr 25, 2026 12:39am
· Source: massive.com